Stent vs. Indomethacin for Preventing Post-ERCP Pancreatitis
Public ClinicalTrials.gov record NCT02476279. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Stent vs. Indomethacin for Preventing Post-ERCP Pancreatitis: The SVI Trial
Study identification
- NCT ID
- NCT02476279
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Medical University of South Carolina
- Other
- Enrollment
- 1,950 participants
Conditions and interventions
Conditions
Interventions
- Indomethacin 100 mg rectally immediately after ERCP, NO prophylactic pancreatic stent placement Other
- Indomethacin 100 mg rectally immediately after ERCP AND prophylactic pancreatic stent placement Other
Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2015
- Primary completion
- Jan 24, 2023
- Completion
- Jan 24, 2023
- Last update posted
- Jun 11, 2024
2015 – 2023
United States locations
- U.S. sites
- 18
- U.S. states
- 17
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Univesrity of Southern California | Los Angeles | California | — | — |
| University of Colorado | Denver | Colorado | — | — |
| The Florida Hospital | Orlando | Florida | — | — |
| Emory University | Atlanta | Georgia | — | — |
| Northwestern University | Chicago | Illinois | — | — |
| University of Kansas | Kansas City | Kansas | — | — |
| Johns Hopkins University | Baltimore | Maryland | — | — |
| University of Michigan | Ann Arbor | Michigan | — | — |
| Washington University | St Louis | Missouri | — | — |
| Dartmouth University | Lebanon | New Hampshire | — | — |
| Case Western Reserve University | Cleveland | Ohio | — | — |
| The Ohio State University Wexner Medical Center | Columbus | Ohio | — | — |
| Oregon Health & Science University | Portland | Oregon | — | — |
| University of Pittsburgh | Pittsburgh | Pennsylvania | — | — |
| Medical University of South Carolina | Charleston | South Carolina | — | — |
| Vanderbilt University | Nashville | Tennessee | — | — |
| Virginia Mason Medical Center | Seattle | Washington | — | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02476279, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 11, 2024 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02476279 live on ClinicalTrials.gov.